Rocket Pharmaceuticals (RCKT) Projected to Release Earnings on Thursday

Rocket Pharmaceuticals (NASDAQ:RCKT) is anticipated to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Rocket Pharmaceuticals to announce earnings of $1.04 per share and revenue of $0.2220 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:00 PM ET.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). During the same quarter in the prior year, the firm posted ($0.56) EPS. On average, analysts expect Rocket Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Rocket Pharmaceuticals Stock Performance

NASDAQ RCKT opened at $3.14 on Thursday. The company’s fifty day simple moving average is $3.27 and its 200-day simple moving average is $3.63. Rocket Pharmaceuticals has a 52 week low of $2.53 and a 52 week high of $5.45. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.08. The stock has a market cap of $342.86 million, a P/E ratio of -1.68 and a beta of 0.45.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Weiss Ratings raised shares of Rocket Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Wall Street Zen cut shares of Rocket Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, Chardan Capital reissued a “buy” rating and issued a $11.00 price objective on shares of Rocket Pharmaceuticals in a research report on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $8.71.

Insider Buying and Selling

In other Rocket Pharmaceuticals news, CEO Gaurav Shah sold 55,684 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $3.09, for a total value of $172,063.56. Following the transaction, the chief executive officer directly owned 1,061,724 shares of the company’s stock, valued at $3,280,727.16. This represents a 4.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Sarbani Chaudhuri sold 17,650 shares of the stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $3.84, for a total value of $67,776.00. Following the transaction, the insider owned 267,510 shares of the company’s stock, valued at approximately $1,027,238.40. This trade represents a 6.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 83,733 shares of company stock worth $275,307. 21.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in RCKT. Vanguard Group Inc. grew its holdings in Rocket Pharmaceuticals by 12.6% during the 3rd quarter. Vanguard Group Inc. now owns 6,892,204 shares of the biotechnology company’s stock worth $22,469,000 after acquiring an additional 769,743 shares in the last quarter. MPM Bioimpact LLC raised its stake in shares of Rocket Pharmaceuticals by 141.2% in the 2nd quarter. MPM Bioimpact LLC now owns 3,903,081 shares of the biotechnology company’s stock valued at $9,563,000 after purchasing an additional 2,284,816 shares in the last quarter. Millennium Management LLC lifted its position in shares of Rocket Pharmaceuticals by 52.0% during the third quarter. Millennium Management LLC now owns 3,570,391 shares of the biotechnology company’s stock worth $11,639,000 after purchasing an additional 1,221,554 shares during the last quarter. Newtyn Management LLC lifted its position in shares of Rocket Pharmaceuticals by 25.1% during the third quarter. Newtyn Management LLC now owns 2,502,863 shares of the biotechnology company’s stock worth $8,159,000 after purchasing an additional 502,863 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Rocket Pharmaceuticals by 10.7% during the fourth quarter. Geode Capital Management LLC now owns 2,120,269 shares of the biotechnology company’s stock worth $7,443,000 after purchasing an additional 205,715 shares during the last quarter. 98.39% of the stock is currently owned by institutional investors.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.